Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Leukemia

Free Subscription Articles published in Cancer Lett Retrieve available abstracts of 33 articles: HTML format

Single Articles

May 2025
1. XIANG G, Zhu P, Zhang L, Yu S, et al
   Effective leukemia-to-granulocyte induction by a cocktail of RUNX1, SPI1 and CEBPE.
   Cancer Lett. 2025;626:217820.
   PubMed    
   
   
   
2. HU LJ, Li CY, Xing T, Wang Y, et al
   N-acetyl-L-cysteine promoted hematopoietic recovery in patients with acute myeloid leukemia after complete remission--A pilot study.
   Cancer Lett. 2025 May 20:217812. doi: 10.1016/j.canlet.2025.217812.
   PubMed     Abstract available
   
   
   April 2025
3. MA XH, Gao MG, Cheng RQ, Qin YZ, et al
   The expression level of EVI1 and clinical features help to distinguish prognostic heterogeneity in the AML entity with EVI1 overexpression.
   Cancer Lett. 2025;615:217547.
   PubMed     Abstract available
   
   
   
4. LIU Y, Tu Y, Yan Z, Xiao J, et al
   CAR T-Cell Therapy in Chronic Myeloid Leukemia Patients with Lymphoid Blast Crisis: A Multicenter Clinical Analysis.
   Cancer Lett. 2025 Apr 1:217688. doi: 10.1016/j.canlet.2025.217688.
   PubMed    
   
   
   March 2025
5. WANG Y, Liu W, Gu Z, Chang Y, et al
   Allogeneic versus autologous hematopoietic stem cell transplantation for adult T-lymphoblastic lymphoma: a real-world multicenter analysis in China.
   Cancer Lett. 2025 Mar 21:217664. doi: 10.1016/j.canlet.2025.217664.
   PubMed     Abstract available
   
   
   February 2025
6. CHEN DW, Schrey JM, Wafula EK, Fan JM, et al
   Leukemia confers a durable imprint on healthy hematopoietic stem and progenitor cells.
   Cancer Lett. 2025;616:217590.
   PubMed     Abstract available
   
   
   
7. LIU C, Liu G, Zhou F, Chen L, et al
   EBF1-induced CSRP2 boosts the progression of B-cell acute lymphocytic leukemia by inhibiting ferroptosis.
   Cancer Lett. 2025;614:217556.
   PubMed     Abstract available
   
   
   January 2025
8. WEISS S, Zdarsky B, Witalisz-Siepracka A, Edtmayer S, et al
   Atovaquone and selinexor as a novel combination treatment option in acute myeloid leukemia.
   Cancer Lett. 2025;613:217501.
   PubMed     Abstract available
   
   
   
9. LI M, Li Y, Qu Q, Wang C, et al
   Clinical features and prognostic nomogram for therapy-related acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
   Cancer Lett. 2025 Jan 11:217460. doi: 10.1016/j.canlet.2025.217460.
   PubMed     Abstract available
   
   
   
10. PEI HZ, Guo Y, Zhao Y, Zhang D, et al
    FLT3 inhibitors induce p53 instability, driven by STAT5/MDM2/p53 competitive interactions in acute myeloid leukemia.
    Cancer Lett. 2025;611:217446.
    PubMed     Abstract available
    
    
    December 2024
11. WANG J, Ma W, Huang J, Qiu G, et al
    Corrigendum to "HIF-2alpha 1 inhibition disrupts leukemia stem cell metabolism and impairs vascular microenvironment to enhance chronic myeloid leukemia treatment" [Cancer lett. 597 (2024) 217060].
    Cancer Lett. 2024 Dec 31:217435. doi: 10.1016/j.canlet.2024.217435.
    PubMed    
    
    
    
12. JIN P, Shen J, Zhao M, Yu J, et al
    Driver mutation landscape of acute myeloid leukemia provides insights for neoantigen-based immunotherapy.
    Cancer Lett. 2024 Dec 24:217427. doi: 10.1016/j.canlet.2024.217427.
    PubMed     Abstract available
    
    
    
13. VAN TRIMPONT M, Schalk AM, Hofkens K, Peeters E, et al
    A human-like glutaminase-free asparaginase is highly efficacious in ASNS(low) leukemia and solid cancer mouse xenograft models.
    Cancer Lett. 2024 Dec 19:217404. doi: 10.1016/j.canlet.2024.217404.
    PubMed     Abstract available
    
    
    November 2024
14. WANG Y, Chang YJ, Chen J, Han M, et al
    Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update.
    Cancer Lett. 2024;605:217264.
    PubMed     Abstract available
    
    
    
15. HLOZKOVA K, Vasylkivska M, Boufersaoui A, Marzullo B, et al
    Rewired glutamate metabolism diminishes cytostatic action of L-asparaginase.
    Cancer Lett. 2024;605:217242.
    PubMed     Abstract available
    
    
    October 2024
16. WANG ZK, Zhang ZW, Lyu ZS, Xing T, et al
    Inhibition of TGF-beta signaling in bone marrow endothelial cells promotes hematopoietic recovery in acute myeloid leukemia patients.
    Cancer Lett. 2024;605:217290.
    PubMed     Abstract available
    
    
    August 2024
17. WANG YQ, Ren Y, Gale RP, Niu LT, et al
    Sphingosine-1 phosphate receptor 1 (S1PR1) expression maintains stemness of acute myeloid leukemia stem cells.
    Cancer Lett. 2024 Aug 5:217158. doi: 10.1016/j.canlet.2024.217158.
    PubMed     Abstract available
    
    
    July 2024
18. LIU T, Gu L, Mui A, Wu Z, et al
    An MDM2 degrader shows potent cytotoxicity to MDM2-overexpressing acute lymphoblastic leukemia cells with minimal toxicity to normal cells/tissues.
    Cancer Lett. 2024 Jul 23:217126. doi: 10.1016/j.canlet.2024.217126.
    PubMed     Abstract available
    
    
    
19. LIU Y, Zheng L, Li Y, Ma L, et al
    Neratinib impairs function of m6A recognition on AML1-ETO pre-mRNA and induces differentiation of t (8;21) AML cells by targeting HNRNPA3.
    Cancer Lett. 2024;594:216980.
    PubMed     Abstract available
    
    
    
20. YAN N, Wang ZL, Wang XJ, Gale RP, et al
    Measurable residual disease testing by next generation sequencing is more accurate compared with multiparameter flow cytometry in adults with B-cell acute lymphoblastic leukemia.
    Cancer Lett. 2024;598:217104.
    PubMed     Abstract available
    
    
    
21. YAO M, Jiang X, Xiao F, Lv X, et al
    Targeting BIRC5 as a therapeutic approach to overcome ASXL1-associated decitabine resistance.
    Cancer Lett. 2024;593:216949.
    PubMed     Abstract available
    
    
    June 2024
22. WANG J, Ma W, Huang J, Qiu G, et al
    HIF-2alpha Inhibition Disrupts Leukemia Stem Cell Metabolism and Impairs Vascular Microenvironment to Enhance Chronic Myeloid Leukemia Treatment.
    Cancer Lett. 2024 Jun 14:217060. doi: 10.1016/j.canlet.2024.217060.
    PubMed     Abstract available
    
    
    
23. YUAN J, Zhang J, Zhao B, Liu F, et al
    Single-cell transcriptomic analysis of the immune microenvironment in pediatric acute leukemia.
    Cancer Lett. 2024 Jun 4:217018. doi: 10.1016/j.canlet.2024.217018.
    PubMed     Abstract available
    
    
    May 2024
24. XU M, Li S
    The opportunities and challenges of using PD-1/PD-L1 inhibitors for leukemia treatment.
    Cancer Lett. 2024;593:216969.
    PubMed     Abstract available
    
    
    
25. WANG D, He J, Liu S, Zhang H, et al
    Anlotinib synergizes with venetoclax to induce mitotic catastrophe in acute myeloid leukemia.
    Cancer Lett. 2024 May 17:216970. doi: 10.1016/j.canlet.2024.216970.
    PubMed     Abstract available
    
    
    
26. TAN Y, Xin L, Wang Q, Xu R, et al
    FLT3-Selective PROTAC: Enhanced Safety and Increased Synergy with Venetoclax in FLT3-ITD Mutated Acute Myeloid Leukemia.
    Cancer Lett. 2024 May 3:216933. doi: 10.1016/j.canlet.2024.216933.
    PubMed     Abstract available
    
    
    April 2024
27. ZHAO Y, Chen W, Yu J, Pei S, et al
    TP53 in MDS and AML: Biological and clinical advances.
    Cancer Lett. 2024;588:216767.
    PubMed     Abstract available
    
    
    
28. SUN H, Xie Y, Wu X, Hu W, et al
    circRNAs as prognostic markers in pediatric acute myeloid leukemia.
    Cancer Lett. 2024;591:216880.
    PubMed     Abstract available
    
    
    March 2024
29. HE Y, Jiang S, Cui Y, Liang J, et al
    Induction of IFIT1/IFIT3 and inhibition of Bcl-2 orchestrate the treatment of myeloma and leukemia via pyroptosis.
    Cancer Lett. 2024 Mar 8:216797. doi: 10.1016/j.canlet.2024.216797.
    PubMed     Abstract available
    
    
    February 2024
30. CHENG C, Liang S, Yue K, Wu N, et al
    STAT5 is essential for inducing the suppressive subset and attenuate cytotoxicity of Vdelta2(+) T cells in acute myeloid leukemia.
    Cancer Lett. 2024 Feb 13:216730. doi: 10.1016/j.canlet.2024.216730.
    PubMed     Abstract available
    
    
    January 2024
31. YANG F, Cui X, Wang H, Zhang D, et al
    Iron overload promotes the progression of MLL-AF9 induced acute myeloid leukemia by upregulation of FOS.
    Cancer Lett. 2024 Jan 17:216652. doi: 10.1016/j.canlet.2024.216652.
    PubMed     Abstract available
    
    
    December 2023
32. JUNG YY, Ahn KS, Shen M
    Unveiling autophagy complexity in leukemia: The molecular landscape and possible interactions with apoptosis and ferroptosis.
    Cancer Lett. 2023 Dec 1:216518. doi: 10.1016/j.canlet.2023.216518.
    PubMed     Abstract available
    
    
    September 2023
33. WEN J, Chen Y, Liao C, Ma X, et al
    Engineered mesenchymal stem cell exosomes loaded with miR-34c-5p selectively promote eradication of acute myeloid leukemia stem cells.
    Cancer Lett. 2023 Sep 26:216407. doi: 10.1016/j.canlet.2023.216407.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.